Meropenem and vaborbactam

(Vabomere®)

Meropenem and vaborbactam

Drug updated on 5/17/2024

Dosage FormInjection (intravenous; 2 g/vial [1 g meropenem (equivalent to 1.14 g meropenem trihydrate) and 1 g vaborbactam])
Drug ClassAntibacterials
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible bacteria.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Meropenem and vaborbactam (Vabomere) is indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI), including pyelonephritis caused by designated susceptible bacteria.
  • Two studies were reviewed to gather information about Vabomere's efficacy and safety in treating cUTIs.
  • The first study, "Novel Antibiotics for cUTIs," suggests that novel antibiotics like Vabomere may offer superior efficacy with similar safety profiles compared to control treatments for cUTI patients.
  • The second study, "Comparison of Carbapenems," indicates that Vabomere has higher treatment success rates against carbapenem-resistant pathogens, but it also presents a higher risk of adverse events compared to other carbapenems.
  • When comparing Vabomere to other treatments for cUTI, it stands out due to its high effectiveness, particularly against carbapenem-resistant organisms; however, there are concerns regarding its safety profile as it might present a higher risk of adverse events than some other carbapenems.
  • The studies emphasize the drug's role in managing infections caused by resistant bacteria, which can be more challenging clinical scenarios.